Bavarian Nordic pivots operations to focus on monkeypox vaccine production

Demand is soaring for the Danish vaccine maker’s shot against the monkeypox disease to a degree that means the company must increase production capacity while changing existing plans.

Paul Chaplin, CEO of Bavarian Nordic | Photo: Bavarian Nordic /PR

Order books at vaccine maker Bavarian Nordic are being filled at a rapid pace as demand surges for the company’s monkeypox vaccine, branded regionally as Imvanex, Jynneos, or Imvamune.

In fact, Bavarian Nordic has been so busy that the company’s production capacity is now being expanded, plans are being rewritten, and other activities are being delayed, in what makes for a full pivot to handling the many monkeypox orders, reports Danish business media Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs